Timing of Extended-Release vs Immediate-Release Medications

ADHD Stimulant Medications

The American Academy of Child and Adolescent Psychiatry recommends immediate-release stimulants be dosed in the morning, with additional doses at noon and potentially at 4 PM as needed to cover the full day 1
Extended-release formulations are designed for once-daily morning dosing to provide all-day coverage and eliminate the need for in-school administration, as recommended by the American Academy of Child and Adolescent Psychiatry 1
The American Academy of Child and Adolescent Psychiatry suggests that adults and older adolescents may require multiple dosings throughout the day to cover longer waking hours, but these are still initiated in the morning 1
Combining short-acting methylphenidate with extended-release formulations is a common practice to increase efficacy and allow more flexible dosing, according to the American Academy of Child and Adolescent Psychiatry 1

Extended-release zolpidem should be taken at bedtime, as recommended by the American College of Physicians, and provides maintained sleep throughout the night while limiting next-day residual effects 2
The American College of Physicians recommends that extended-release formulations provide more consistent plasma levels throughout the dosing period, reducing the "hangover effect" commonly associated with sedating medications, although this fact is from the Annals of Internal Medicine, a more relevant guideline is not available 3
Sublingual zolpidem (3.5 mg) can be taken as needed for middle-of-the-night awakenings, as recommended by the American College of Physicians 2
The FDA recommends lower starting doses for extended-release zolpidem (6.25 mg) to reduce next-day sedation compared to immediate-release formulations, as stated in the guideline from the FDA 3

The Centers for Disease Control and Prevention recommends that when starting opioid therapy for chronic pain, clinicians should prescribe immediate-release opioids instead of extended-release/long-acting (ER/LA) opioids, based on a Category A recommendation 4
The Centers for Disease Control and Prevention states that ER/LA opioids should be reserved for "management of pain severe enough to require daily, around-the-clock, long-term opioid treatment" when alternative options are inadequate, based on a Category A recommendation 4
Time-scheduled opioid use is associated with greater total average daily opioid dosage compared with intermittent, as-needed use, as reported by the Centers for Disease Control and Prevention 4
There is insufficient evidence to determine the safety of using immediate-release opioids for breakthrough pain when ER/LA opioids are used for chronic pain outside of cancer/palliative care, and this practice may be associated with dose escalation, according to the Centers for Disease Control and Prevention 4

The American Diabetes Association recommends that preferential use of antihypertensives at bedtime is not recommended based on recent randomized clinical trials that failed to reproduce earlier findings suggesting benefit to evening dosing 8

The American College of Emergency Physicians recommends that long-acting or extended-release Schedule II opioids (OxyContin, MS Contin, fentanyl patches) should not be used for acute pain - these are indicated only for chronic pain in opioid-tolerant patients, although a more relevant guideline society is not available 7
The American Academy of Child and Adolescent Psychiatry advises against assuming all extended-release formulations should be taken at night - most ADHD stimulants and many other medications require morning dosing despite being extended-release 1
Individual patient factors including age, hepatic function, and concomitant medications can significantly affect medication metabolism and influence optimal timing, as stated in the guideline, although a more relevant guideline society is not available 3